Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.7K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.7K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

377
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
377
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

311
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolated Occipital Lobe Hypometabolism on [<sup>18</sup>F]FDG PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Multisystemic Malakoplakia Revealed by 18 F-FDG PET/CT: A Case of Concomitant Bilateral Osteomyelitis and Genitourinary Involvement.

Clinical nuclear medicine·2026
Same author

FDG-PET/CT for Effective Staging of Disseminated Blastomycosis.

Clinical nuclear medicine·2025
Same author

Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.

Frontiers in oncology·2025
Same author

Variants of physiological FDG vascular activity on digital PET.

Nuclear medicine communications·2024
Same author

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2024

Related Experiment Video

Updated: Dec 13, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.4K

Weight loss as primary indication for FDG-PET/CT.

Peter George Maliha1, Julia Singerman2, Stephan Probst1

  • 1Nuclear Medicine Department, Sir Mortimer B. Davis - Jewish General Hospital, Faculty of Medicine, McGill University.

Nuclear Medicine Communications
|August 1, 2020
PubMed
Summary

Fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) has limited clinical value for unexplained weight loss. The diagnostic imaging was found to be detrimental more often than beneficial in this patient group.

More Related Videos

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

18.6K
Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT
10:53

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Published on: November 23, 2012

19.6K

Related Experiment Videos

Last Updated: Dec 13, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.4K
Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

18.6K
Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT
10:53

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Published on: November 23, 2012

19.6K

Area of Science:

  • Nuclear Medicine
  • Diagnostic Imaging
  • Oncology

Background:

  • Unexplained weight loss is a common clinical concern, often prompting investigation for malignancy.
  • Fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) is sometimes considered for patients with nonspecific symptoms, including weight loss.
  • The clinical utility of FDG-PET/CT in this specific patient population requires further evaluation.

Purpose of the Study:

  • To assess the clinical value of FDG-PET/CT in patients referred primarily for the indication of weight loss.
  • To determine the appropriateness of using FDG-PET/CT for evaluating unexplained weight loss.

Main Methods:

  • A retrospective study of 234 patients who underwent 236 FDG-PET/CT scans for weight loss between 2010 and 2017.
  • Scans were categorized as clinically beneficial, neutral, or detrimental based on diagnostic accuracy and impact on subsequent management.
  • Exclusion criteria included active malignancy, weight loss not being the primary indication, inadequate scan quality, and insufficient follow-up.

Main Results:

  • FDG-PET/CT scans were true positive in 10% of cases, with only 3% deemed clinically beneficial.
  • False positive results occurred in 16% of scans, leading to additional procedures in many instances.
  • Overall, 17% of FDG-PET/CT studies were clinically detrimental, while 63% were true negative and clinically neutral.

Conclusions:

  • FDG-PET/CT demonstrates limited clinical value when weight loss is the primary indication for the scan.
  • The imaging modality is significantly more likely to be detrimental than beneficial in this clinical scenario.
  • Current evidence suggests caution in the routine use of FDG-PET/CT for evaluating patients with unexplained weight loss.